PA
ABOS icon

Pinnacle Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Pinnacle Associates’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.5K Hold
18,020
– – ﹤0.01% 950
2025
Q4 		$38K Hold
18,020
– – ﹤0.01% 926
2025
Q3 		$30.8K Hold
18,020
– – ﹤0.01% 861
2025
Q2 		$20.9K Hold
18,020
– – ﹤0.01% 843
2025
Q1 		$19.8K Hold
18,020
– – ﹤0.01% 820
2024
Q4 		$31K Buy
+18,020
New +$43.4K ﹤0.01% 830
2024
Q3 		– Sell
-18,020
Closed -$43.6K – 801
2024
Q2 		$43.6K Hold
18,020
– – ﹤0.01% 805
2024
Q1 		$73K Buy
+18,020
New +$67.9K ﹤0.01% 820
2023
Q4 		– Sell
-18,020
Closed -$74.8K – 819
2023
Q3 		$74.8K Hold
18,020
– – ﹤0.01% 793
2023
Q2 		$86.7K Buy
+18,020
New +$86.3K ﹤0.01% 793

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Pinnacle Associates's ABOS Position: Q1 2026 in Review

Pinnacle Associates held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 18,020 shares worth $42.5K. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Pinnacle Associates first reported a position in ABOS in Q2 2023 and has held it in 10 quarters since. The position peaked at $86.7K in Q2 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Pinnacle Associates held 18,020 shares of Acumen Pharmaceuticals worth $42.5K as of Q1 2026.
  • Pinnacle Associates left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Pinnacle Associates's portfolio in Q1 2026, its #950 holding.
  • Pinnacle Associates first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
  • Pinnacle Associates's Acumen Pharmaceuticals position peaked at $86.7K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.